Clinical Trial Update: SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I [Phase 3]

View source ↗

Summary

Phase 3 trial SHTC EUROPE-1 evaluating Synergo hyperthermia-chemotherapy for urinary bladder neoplasms has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms
• Neoplasms By Site
• Urinary Bladder Diseases
• Urinary Bladder Neoplasms
• Urogenital Neoplasms
• Urologic Diseases
• Urologic Neoplasms

Drugs mentioned

• Mitomycin-C (mitomycin C)

Snippet

Sponsor: Medical Enterprises Europe B.V. | Conditions: Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 3 | Status: WITHDRAWN